[Complete remission in erythroleukemia: induced with low dose Ara-C, consolidated with high dose Ara-C].
A 20-year-old man was admitted because of general fatigue. Peripheral blood examination revealed pancytopenia (WBC 1,700/microliters, RBC 210 x 10(4)/microliters, Plt 3.2 x 10(4)/microliters) with remarkable erythroblastosis. Bone marrow examination revealed erythroid hyperplasia and an increase of abnormal myeloblasts with Auer bodies (37% of non erythroid cells). A diagnosis of erythroleukemia (AML M6) was made. He received two courses of combination chemotherapy (BHAC-DMP and VAMA (VP-16, Ara-C, 6-MP, and doxorubicin (ADR)) but complete remission (CR) could not be achieved. Consequently, he was treated with LDAC. After two courses of LDAC. CR was obtained. Subsequently, he received two courses of HDAC as consolidation, and therapy has been off thereafter. He remains in CR state for more than 12 months.
Imoto
S
S
Department of Internal Medicine, Hyogo Medical Center For Adults.
Ito
M
M
Nakagawa
T
T
D000328:Adult; D003561:Cytarabine / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D006801:Humans; D004915:Leukemia, Erythroblastic, Acute / Q000188:drug therapy*; D008297:Male; D008942:Mitoxantrone / Q000008:administration & dosage; D012074:Remission Induction
D003561:Cytarabine; D008942:Mitoxantrone